Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx(R)-265
December 08 2010 - 2:03PM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") is pleased to announce today that it has been granted a
patent by the U.S. Patent and Trademark Office -U.S. Patent
7,846,898- entitled, "Pheromones and the luteinizing hormone for
inducing proliferation of neural stem cells and neurogenesis." The
claims cover the use of luteinizing hormone (LH) or human chorionic
gonadotrophin (hCG) and erythropotein (EPO) for producing neural
stem cells (in vitro & in vivo), which can in turn produce more
neurons or glial cells to compensate for lost or dysfunctional
neural cells. The covered in vivo uses include administration of
these compounds to subjects having neurodegenerative conditions,
diseases and CNS injuries. This is the first U.S. patent to issue
in this patent family and it protects the use of the NTx®-265
regimen in the acute neurologic injury indications of Stroke, and
Traumatic Brain Injury, amongst other indications.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as
follows:
"We at SCT are very excited to see this patent issue as it
represents an important intellectual property milestone for the
NTx®-265 program. This patent offers protection and support for our
NTx®-265 technology, a keystone patent, while expanding and
increasing value to SCT's overall intellectual property
portfolio."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX-V: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO
403-245-5495 ext.226 adavidoff@stemcellthera.com Stem Cell
Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager
403-245-5495 ext. 230 adasilva@stemcellthera.com Stem Cell
Therapeutics Corp. Michael Cook CFO 403-245-5495 ext.229
mcook@stemcellthera.com www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024